1. Home
  2. VSTM
  3. VSTM News

Latest Verastem Inc. (VSTM) News on May 10, 2025

VSTM

MT Newswires

14 hours ago

RBC Raises Price Target on Verastem to $16 From $14, Keeps Outperform, Speculative Risk

FDA Grants Accelerated Approval To Verastem's Combination Drug For Ovarian Cancer
VSTM

Benzinga

a day ago

FDA Grants Accelerated Approval To Verastem's Combination Drug For Ovarian Cancer

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer
VSTM

Business Wire

a day ago

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

VSTM

MT Newswires

a day ago

Verastem Receives US FDA Approval for Drug Combination to Treat Recurrent Ovarian Cancer

Verastem Oncology to Present at Upcoming Investor Conferences
VSTM

Business Wire

9 days ago

Verastem Oncology to Present at Upcoming Investor Conferences

VSTM

MT Newswires

12 days ago

B. Riley Adjusts Verastem Price Target to $12 From $9, Maintains Buy Rating

VSTM

MT Newswires

15 days ago

Verastem Shares Rise After Agreement to Sell Securities Worth Roughly $75 Million

Verastem Oncology Announces $75 million Private Placement
VSTM

Business Wire

15 days ago

Verastem Oncology Announces $75 million Private Placement

Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors
VSTM

Business Wire

16 days ago

Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors

Verastem Oncology to Report Q1 Earnings: What's in the Cards?
VSTM

Zacks

18 days ago

Verastem Oncology to Report Q1 Earnings: What's in the Cards?

Top Cancer Stocks to Buy to Boost Your Portfolio's Health
VSTM

Zacks

24 days ago

Top Cancer Stocks to Buy to Boost Your Portfolio's Health

VSTM

MT Newswires

a month ago

Jefferies Initiates Verastem at Buy With $15 Price Target

VSTM

MT Newswires

a month ago

Mizuho Securities Adjusts Verastem Price Target to $8 From $9, Maintains Outperform Rating

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VSTM

Business Wire

a month ago

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to Trade
VSTM

Zacks

a month ago

Wall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to Trade

Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025
VSTM

Business Wire

a month ago

Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025

VSTM

MT Newswires

2 months ago

RBC Cuts Price Target on Verastem to $14 From $16, Maintains Outperform Rating

VSTM

Associated Press Finance

2 months ago

Verastem: Q4 Earnings Snapshot

Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
VSTM

Business Wire

2 months ago

Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer
VSTM

Business Wire

3 months ago

Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

VSTM

MT Newswires

3 months ago

B. Riley Adjusts Verastem's Price Target to $9 From $7, Maintains Buy Rating

Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference
VSTM

Business Wire

3 months ago

Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference

Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers
VSTM

Business Wire

4 months ago

Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers

VSTM

MT Newswires

4 months ago

Verastem Names Matthew E. Ros as COO

Verastem Oncology Names Matthew E. Ros as Chief Operating Officer
VSTM

Business Wire

4 months ago

Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

VSTM

MT Newswires

4 months ago

Verastem Exercises Option Early to License Cancer Drug VS-7375 From GenFleet

Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China
VSTM

Business Wire

4 months ago

Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China

Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025
VSTM

Business Wire

4 months ago

Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VSTM

Business Wire

4 months ago

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VSTM

MT Newswires

4 months ago

RBC Raises Price Target on Verastem to $16 From $13, Keeps Outperform, Speculative Risk

VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag
VSTM

Zacks

4 months ago

VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag

Verastem Shares Surge Over 24% on FDA Acceptance of Cancer Therapy Application
VSTM

GuruFocus.com

4 months ago

Verastem Shares Surge Over 24% on FDA Acceptance of Cancer Therapy Application

VSTM

MT Newswires

4 months ago

Traders Cautious as 2024 Draws to Close, Stifling US Equity Futures Pre-Bell

VSTM

MT Newswires

4 months ago

Top Premarket Gainers

VSTM

MT Newswires

4 months ago

BTIG Raises Price Target on Verastem to $20 From $13, Keeps Buy Rating

VSTM

MT Newswires

4 months ago

Verastem's Ovarian Cancer Drug Application Accepted by FDA, Gets Priority Review

Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
VSTM

Business Wire

4 months ago

Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Applied Therapeutics Appoints John H. Johnson as Executive Chairman
VSTM

GlobeNewswire

5 months ago

Applied Therapeutics Appoints John H. Johnson as Executive Chairman

VSTM

MT Newswires

5 months ago

Mizuho Raises Price Target on Verastem to $9 From $7, Keeps Outperform Rating

Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
VSTM

Business Wire

5 months ago

Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference
VSTM

Business Wire

5 months ago

Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference

VSTM

Associated Press Finance

6 months ago

Verastem: Q3 Earnings Snapshot

Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
VSTM

Business Wire

6 months ago

Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Verastem Oncology submits NDA for ovarian cancer treatment
VSTM

Pharmaceutical Technology

6 months ago

Verastem Oncology submits NDA for ovarian cancer treatment

VSTM

MT Newswires

6 months ago

Verastem Completes Rolling NDA Submission to US FDA for Drug Combination to Treat Rare Ovarian Cancer

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
VSTM

Business Wire

6 months ago

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Verastem Oncology to Participate in Upcoming Investor Conferences
VSTM

Business Wire

6 months ago

Verastem Oncology to Participate in Upcoming Investor Conferences

VSTM

MT Newswires

7 months ago

Verastem Reports Updated Data on Phase 2 Study of Ovarian Cancer Combination Therapy

Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting
VSTM

Business Wire

7 months ago

Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting

Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting
VSTM

Business Wire

7 months ago

Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VSTM

Business Wire

7 months ago

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VSTM

MT Newswires

7 months ago

Guggenheim Initiates Coverage on Verastem With Buy Rating, $13 Price Target

Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference
VSTM

Business Wire

8 months ago

Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference

Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting
VSTM

Business Wire

8 months ago

Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting

Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024
VSTM

Business Wire

8 months ago

Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024

VSTM

MT Newswires

9 months ago

RBC Adjusts Price Target on Verastem to $13 From $16, Maintains Outperform Rating

VSTM

Associated Press Finance

9 months ago

Verastem: Q2 Earnings Snapshot

Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates
VSTM

Business Wire

9 months ago

Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates

VSTM

MT Newswires

9 months ago

Verastem Gets FDA Orphan Drug Designation for Avutometinib With Defactinib to Treat Pancreatic Cancer

Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer
VSTM

Business Wire

9 months ago

Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer

VSTM

MT Newswires

10 months ago

B. Riley Adjusts Verastem's PT to $7 From $21, Maintains Buy Rating

VSTM

MT Newswires

10 months ago

Top Premarket Decliners

Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants
VSTM

Business Wire

10 months ago

Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants

Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants
VSTM

Business Wire

10 months ago

Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants

Verastem (VSTM) Begins Dosing in Solid Tumors Study in China
VSTM

Zacks

10 months ago

Verastem (VSTM) Begins Dosing in Solid Tumors Study in China

Verastem announces dosing of first patient in trial of KRAS G12D inhibitor
VSTM

Clinical Trials Arena

10 months ago

Verastem announces dosing of first patient in trial of KRAS G12D inhibitor

VSTM

MT Newswires

10 months ago

Sector Update: Health Care Stocks Higher in Late Afternoon Trading

VSTM

MT Newswires

10 months ago

Verastem Says First Patient Dosed in Phase 1/2 Solid Tumor Trial in China

Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics
VSTM

Business Wire

10 months ago

Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VSTM

Business Wire

10 months ago

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VSTM

MT Newswires

10 months ago

Truist Securities Adjusts Price Target on Verastem to $18 From $34, Notes Recent Stock Pull Back; Maintains Buy Rating

Verastem Oncology Announces Addition to Russell 3000® and Russell Microcap® Indexes
VSTM

Business Wire

10 months ago

Verastem Oncology Announces Addition to Russell 3000® and Russell Microcap® Indexes

VSTM

MT Newswires

a year ago

RBC Halves Price Target on Verastem to $16 From $32, Maintains Outperform Rating, Speculative Risk Qualifier

VSTM

MT Newswires

a year ago

Top Midday Decliners

Verastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data
VSTM

Zacks

a year ago

Verastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data

What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?
VSTM

Benzinga

a year ago

What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?

VSTM

MT Newswires

a year ago

Sector Update: Health Care Stocks Advance Pre-Bell Friday

ASCO 2024: Verastem’s combo therapy for pancreatic cancer hits early trial success
VSTM

Pharmaceutical Technology

a year ago

ASCO 2024: Verastem’s combo therapy for pancreatic cancer hits early trial success

ASCO 2024: Verastem’s combo therapy for pancreatic cancer hits early trial success
VSTM

Clinical Trials Arena

a year ago

ASCO 2024: Verastem’s combo therapy for pancreatic cancer hits early trial success

VSTM

MT Newswires

a year ago

Verastem Reports Results of Potential Pancreatic Cancer Treatment, Submits Rolling New Drug Application for Rare Ovarian Cancer

Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
VSTM

Business Wire

a year ago

Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer​
VSTM

Business Wire

a year ago

Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer​

VSTM

Associated Press Finance

a year ago

Verastem: Q1 Earnings Snapshot

Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
VSTM

Business Wire

a year ago

Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates

Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference
VSTM

Business Wire

a year ago

Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference

Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer
VSTM

Business Wire

a year ago

Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VSTM

Business Wire

a year ago

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer
VSTM

Business Wire

a year ago

Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer

VSTM

Associated Press Finance

a year ago

Verastem: Q4 Earnings Snapshot

Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
VSTM

Business Wire

a year ago

Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates

Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs
VSTM

Business Wire

a year ago

Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs

Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
VSTM

Business Wire

a year ago

Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024
VSTM

Business Wire

a year ago

Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024

Andreas Halvorsen's Viking Global Investors LP Bolsters Position in Verastem Inc
VSTM

GuruFocus.com

a year ago

Andreas Halvorsen's Viking Global Investors LP Bolsters Position in Verastem Inc

Director Robert Gagnon Sells 9,204 Shares of Verastem Inc (VSTM)
VSTM

GuruFocus.com

a year ago

Director Robert Gagnon Sells 9,204 Shares of Verastem Inc (VSTM)

3 Stocks That AI Predicts Will Deliver Triple-Digit Returns This Year: February 2024
VSTM

InvestorPlace

a year ago

3 Stocks That AI Predicts Will Deliver Triple-Digit Returns This Year: February 2024

GCM Grosvenor to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Investor Conference Call on February 13, 2024
VSTM

GlobeNewswire

a year ago

GCM Grosvenor to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Investor Conference Call on February 13, 2024

Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers
VSTM

Business Wire

a year ago

Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers

LSI Industries (NASDAQ:LYTS) Has Affirmed Its Dividend Of $0.05
VSTM

Simply Wall St.

a year ago

LSI Industries (NASDAQ:LYTS) Has Affirmed Its Dividend Of $0.05

Blackstone and Other Asset Manager Stocks Have Soared. Earnings Shouldn’t Disappoint.
VSTM

Barrons.com

a year ago

Blackstone and Other Asset Manager Stocks Have Soared. Earnings Shouldn’t Disappoint.

Share on Social Networks: